JP2019513395A5 - - Google Patents

Download PDF

Info

Publication number
JP2019513395A5
JP2019513395A5 JP2018554006A JP2018554006A JP2019513395A5 JP 2019513395 A5 JP2019513395 A5 JP 2019513395A5 JP 2018554006 A JP2018554006 A JP 2018554006A JP 2018554006 A JP2018554006 A JP 2018554006A JP 2019513395 A5 JP2019513395 A5 JP 2019513395A5
Authority
JP
Japan
Prior art keywords
seq
sequence
nucleic acid
effector
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018554006A
Other languages
English (en)
Japanese (ja)
Other versions
JP7236195B2 (ja
JP2019513395A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2017/050330 external-priority patent/WO2017177277A1/en
Publication of JP2019513395A publication Critical patent/JP2019513395A/ja
Publication of JP2019513395A5 publication Critical patent/JP2019513395A5/ja
Application granted granted Critical
Publication of JP7236195B2 publication Critical patent/JP7236195B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018554006A 2016-04-14 2017-04-13 眼咽頭筋ジストロフィー(opmd)の処置のための試薬およびその使用 Active JP7236195B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662322745P 2016-04-14 2016-04-14
US62/322,745 2016-04-14
PCT/AU2017/050330 WO2017177277A1 (en) 2016-04-14 2017-04-13 Reagents for treatment of oculopharyngeal muscular dystrophy (opmd) and use thereof

Publications (3)

Publication Number Publication Date
JP2019513395A JP2019513395A (ja) 2019-05-30
JP2019513395A5 true JP2019513395A5 (https=) 2020-04-23
JP7236195B2 JP7236195B2 (ja) 2023-03-09

Family

ID=60041243

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018554006A Active JP7236195B2 (ja) 2016-04-14 2017-04-13 眼咽頭筋ジストロフィー(opmd)の処置のための試薬およびその使用

Country Status (14)

Country Link
US (1) US11234994B2 (https=)
EP (1) EP3443091A4 (https=)
JP (1) JP7236195B2 (https=)
KR (1) KR102353847B1 (https=)
CN (1) CN109219659B (https=)
AU (1) AU2017250017B2 (https=)
CA (1) CA3020754C (https=)
IL (1) IL262337B2 (https=)
MX (1) MX2018012545A (https=)
NZ (1) NZ747314A (https=)
RU (1) RU2755544C2 (https=)
SG (1) SG11201808981XA (https=)
WO (1) WO2017177277A1 (https=)
ZA (1) ZA201807589B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ747314A (en) 2016-04-14 2022-07-29 Benitec Ip Holdings Inc Reagents for treatment of oculopharyngeal muscular dystrophy (opmd) and use thereof
JP7233149B2 (ja) * 2016-12-14 2023-03-06 ベニテック アイピー ホールディングス インコーポレーテッド 眼咽頭型筋ジストロフィー(opmd)を治療するための試薬及びその使用
JP2022508835A (ja) * 2018-10-17 2022-01-19 ベニテック バイオファーマ リミテッド 眼咽頭筋ジストロフィー(opmd)を治療するための方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677437A (en) 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
MY107332A (en) 1990-08-03 1995-11-30 Sterling Drug Inc Compounds and methods for inhibiting gene expression.
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
EP0642589A4 (en) 1992-05-11 1997-05-21 Ribozyme Pharm Inc METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION.
US5977343A (en) 1992-05-14 1999-11-02 Ribozyme Pharmaceuticals, Inc. Synthesis, deprotection, analysis and purification of RNA and ribozymes
HU9501974D0 (en) 1993-03-31 1995-09-28 Sterling Winthrop Inc Oligonucleotides with amide linkages replacing phosphodiester linkages
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US6001311A (en) 1997-02-05 1999-12-14 Protogene Laboratories, Inc. Apparatus for diverse chemical synthesis using two-dimensional array
US6054576A (en) 1997-10-02 2000-04-25 Ribozyme Pharmaceuticals, Inc. Deprotection of RNA
DE69941447D1 (de) 1998-01-05 2009-11-05 Univ Washington Erhöhter transport unter benutzung membranzerstörender stoffe
US7273933B1 (en) 1998-02-26 2007-09-25 Isis Pharmaceuticals, Inc. Methods for synthesis of oligonucleotides
US6867294B1 (en) 1998-07-14 2005-03-15 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6995259B1 (en) 1998-10-23 2006-02-07 Sirna Therapeutics, Inc. Method for the chemical synthesis of oligonucleotides
US6465628B1 (en) 1999-02-04 2002-10-15 Isis Pharmaceuticals, Inc. Process for the synthesis of oligomeric compounds
AU2001227965A1 (en) 2000-01-21 2001-07-31 Geron Corporation 2'-arabino-fluorooligonucleotide n3'-p5'phosphoramidates: their synthesis and use
WO2002018405A2 (en) 2000-09-01 2002-03-07 Ribozyme Pharmaceuticals, Incorporated Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives
CA2429814C (en) 2000-12-01 2014-02-18 Thomas Tuschl Rna interference mediating small rna molecules
US20020130430A1 (en) 2000-12-29 2002-09-19 Castor Trevor Percival Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products
EP1390490B1 (en) 2001-05-24 2009-04-15 Genzyme Corporation Muscle-specific expression vectors
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
US20030215395A1 (en) 2002-05-14 2003-11-20 Lei Yu Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
US6989442B2 (en) 2002-07-12 2006-01-24 Sirna Therapeutics, Inc. Deprotection and purification of oligonucleotides and their derivatives
WO2004020605A2 (en) 2002-08-29 2004-03-11 The Board Of Trustees Of The Leland Stanford Junior University Circular nucleic acid vectors, and methods for making and using the same
AU2003295600A1 (en) * 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
US7358223B2 (en) 2004-10-04 2008-04-15 Nitto Denko Corporation Biodegradable cationic polymers
US20090023671A1 (en) 2005-01-06 2009-01-22 Brashears Sarah J Rnai Agents for Maintenance of Stem Cells
WO2007086881A2 (en) 2005-02-14 2007-08-02 Sirna Therapeutics, Inc. Cationic lipids and formulated molecular compositions containing them
US8110184B2 (en) * 2005-09-30 2012-02-07 University Of Kentucky Research Foundation Ex vivo and in vivo methods and related compositions for generating hematopoietic stem cell populations
EP2014281A1 (en) 2007-06-19 2009-01-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of inhibitors of sirtuins and/or ampk for the preparation of a medicament for the treatment of polyalanine diseases.
WO2010021865A1 (en) 2008-08-18 2010-02-25 Merck Sharp & Dohme Corp. Novel lipid nanoparticles and novel components for delivery of nucleic acids
CA2740000C (en) 2008-10-09 2017-12-12 Tekmira Pharmaceuticals Corporation Improved amino lipids and methods for the delivery of nucleic acids
WO2010080724A1 (en) 2009-01-12 2010-07-15 Merck Sharp & Dohme Corp. Novel lipid nanoparticles and novel components for delivery of nucleic acids
AU2010223967B2 (en) 2009-03-12 2015-07-30 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
ES2579936T3 (es) 2009-08-20 2016-08-17 Sirna Therapeutics, Inc. Nuevos lípidos catiónicos con diversos grupos de cabeza para el suministro oligonucleotídico
US20120296403A1 (en) * 2010-02-10 2012-11-22 Novartis Ag Methods and compounds for muscle growth
CA2822958A1 (en) 2010-12-30 2012-07-05 Dow Agrosciences Llc Nucleic acid molecules that confer resistance to coleopteran pests
KR101454425B1 (ko) * 2012-10-11 2014-11-03 포항공과대학교 산학협력단 미리세틴을 유효성분으로 포함하는 운동수행능력 증강용 조성물
WO2014077693A1 (en) 2012-11-16 2014-05-22 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Means and methods for reducing an effect of aging in a mammalian cell
KR101683964B1 (ko) * 2014-05-29 2016-12-09 연세대학교 산학협력단 Daxx의 발현을 억제하는 핵산 분자, TRAIL 유전자 및 Bcl-xL 의 발현을 억제하는 핵산 분자를 포함하는 재조합 발현 벡터
NZ747314A (en) 2016-04-14 2022-07-29 Benitec Ip Holdings Inc Reagents for treatment of oculopharyngeal muscular dystrophy (opmd) and use thereof

Similar Documents

Publication Publication Date Title
EP2633051B1 (en) Hbv treatment
CN101603042B (zh) 可用于乙型肝炎病毒感染治疗的rna干扰靶点
US9518260B2 (en) Pain treatment
JP2005521393A5 (https=)
JP2022185052A5 (https=)
JP2025016451A5 (https=)
JP2010500025A5 (https=)
JP2020503014A5 (https=)
AU2021213253A1 (en) Gene therapy for neurodegenerative disorders using polynucleotide silencing and replacement
JP2019513395A5 (https=)
JP2022501044A5 (https=)
JP2024119830A5 (https=)
IL267353B2 (en) Reagents for the treatment of (OCULOPHARYNGEAL MUSCULAR DYSTROPHY (OPMD) and their uses
JP2022536945A5 (https=)
CN103275971A (zh) 可用于乙型肝炎病毒感染治疗的rna干扰靶点
JP2021534796A5 (https=)
US9970004B2 (en) Nucleic acid molecule, expression cassette, expression vector, eukaryotic host cell, induction method of RNA interferencde in eukaryotic host and use of the nucleic acid molecule in therapy of diseases induced by expansion of trinucleotide CAG repeats
JP2022522166A5 (https=)
RU2018138271A (ru) Реагенты для лечения окулофарингеальной мышечной дистрофии (OPMD) и их применение
JP2019514401A5 (https=)
JP2026502888A (ja) エピジェネティック調節因子の新規阻害剤
WO2009002918A2 (en) Hepatitis c dsrna effector molecules, expression constructs, compositions, and methods of use
JP2022508835A5 (https=)
RU2018142797A (ru) Средства для лечения инфекции вируса гепатита в (hbv) и их применение
JP2008503569A5 (https=)